UPDATED May 25, 2024
Companys with strong funding and high growth potential
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
BOVN.F | kr4.70 | 0% | n/a | kr2.7b | kr12.58 | PS9.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
0RV2 | kr238.40 | 2.2% | -24.6% | kr21.1b | kr368.00 | PS83.5x | E50.5% | 0% | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
0A8R | US$228.95 | 4.6% | 81.1% | US$43.2b | US$229.12 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IMGN | US$31.23 | 6.6% | 617.9% | US$8.4b | US$28.95 | PS29.1x | E45.8% | n/a | Pharmaceuticals & Biotech | ||
IPHY.F | €2.20 | 0% | n/a | €215.8m | €5.21 | PS3.5x | E32.8% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$1.93 | -19.6% | 34.5% | US$230.1m | US$9.23 | PB1.3x | E69.8% | n/a | Pharmaceuticals & Biotech | ||
0A8K | US$31.24 | 6.4% | 658.3% | US$8.4b | US$29.16 | PS29.1x | E45.9% | n/a | Pharmaceuticals & Biotech | ||
0EVI | €2.65 | 10.0% | -4.2% | €215.8m | €6.27 | PS3.5x | E32.8% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$6.75 | -13.6% | 106.4% | US$1.6b | US$13.83 | PS9.9x | E60.7% | n/a | Pharmaceuticals & Biotech | ||
BRCT.F | kr22.03 | 1.5% | n/a | kr21.1b | kr34.01 | PS83.5x | E50.5% | 0% | Pharmaceuticals & Biotech | ||
IPHA | €2.90 | 7.1% | -0.1% | €215.8m | €6.87 | PS3.5x | E32.8% | n/a | Pharmaceuticals & Biotech | ||
LEGN | US$41.41 | -8.3% | -34.4% | US$7.5b | US$83.03 | PS22x | E63.3% | n/a | Pharmaceuticals & Biotech | ||
ISEE | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | Pharmaceuticals & Biotech | ||
MSB | AU$1.18 | 8.8% | 9.3% | AU$1.3b | AU$1.10 | PS119.1x | E56.8% | n/a | Pharmaceuticals & Biotech | ||
CLRB | US$3.11 | -5.8% | 103.3% | US$111.5m | US$15.00 | PB12.3x | E61.8% | n/a | Pharmaceuticals & Biotech | ||
SLNO | US$41.16 | -10.8% | 684.0% | US$1.5b | US$68.14 | PB10.5x | E61.5% | n/a | Pharmaceuticals & Biotech | ||
CSPH.F | HK$0.12 | 0% | n/a | HK$1.7b | n/a | PS3.3x | E98.1% | n/a | Pharmaceuticals & Biotech | ||
MGTX | US$5.29 | -7.4% | -19.6% | US$339.9m | US$21.20 | PS29.9x | E56.1% | n/a | Pharmaceuticals & Biotech | ||
MDGL | US$229.58 | 4.3% | -19.4% | US$4.9b | US$363.86 | PB5.8x | E64.3% | n/a | Pharmaceuticals & Biotech | ||
SPRY | US$8.98 | -0.6% | 21.8% | US$870.1m | US$19.00 | PS87011.9x | E58.7% | n/a | Pharmaceuticals & Biotech | ||
IVBI.Y | HK$19.48 | 0% | n/a | HK$58.4b | HK$29.97 | PS8.7x | E50.8% | n/a | Pharmaceuticals & Biotech | ||
0JDK | US$10.10 | -2.0% | 36.1% | US$2.8b | US$26.14 | PS1471.2x | E66.3% | n/a | Pharmaceuticals & Biotech | ||
CAPR | US$5.99 | -3.4% | 32.8% | US$188.7m | US$19.80 | PS7x | E66.2% | n/a | Pharmaceuticals & Biotech |